{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:58:44Z","timestamp":1790794724472,"version":"4.1.0"},"reference-count":154,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03562-9","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:30:21Z","timestamp":1790793021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring Novel Strategies for Improving the Bioavailability of Docetaxel"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-2531","authenticated-orcid":false,"given":"Oly","family":"Katari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-3281","authenticated-orcid":false,"given":"Siddhesh","family":"Warke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-9563","authenticated-orcid":false,"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"4","key":"3562_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1470-2045(05)70094-2","volume":"6","author":"A Montero","year":"2005","unstructured":"Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol. 2005;6(4):229\u201339. https:\/\/doi.org\/10.1016\/S1470-2045(05)70094-2.","journal-title":"Lancet Oncol"},{"issue":"7\u20138","key":"3562_CR2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.18632\/oncoscience.444","volume":"5","author":"Q Du","year":"2018","unstructured":"Du Q, Jiang G, Li S, Liu Y, Huang Z. Docetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis. Oncoscience. 2018;5(7\u20138):220\u201338. https:\/\/doi.org\/10.18632\/oncoscience.444.","journal-title":"Oncoscience"},{"issue":"6","key":"3562_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/cmdc.201200052","volume":"7","author":"P Zhao","year":"2012","unstructured":"Zhao P, Astruc D. Docetaxel nanotechnology in anticancer therapy. ChemMedChem. 2012;7(6):952\u201372. https:\/\/doi.org\/10.1002\/cmdc.201200052.","journal-title":"ChemMedChem"},{"key":"3562_CR4","doi-asserted-by":"publisher","unstructured":"Zhang N, Zhang. How nanotechnology can enhance docetaxel therapy. IJN. 2013;2927. https:\/\/doi.org\/10.2147\/IJN.S46921.","DOI":"10.2147\/IJN.S46921"},{"issue":"1","key":"3562_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543776.2016.1111872","volume":"26","author":"I Ojima","year":"2016","unstructured":"Ojima I, Lichtenthal B, Lee S, Wang C, Wang X. Taxane anticancer agents: a patent perspective. Expert Opin Ther Pat. 2016;26(1):1\u201320. https:\/\/doi.org\/10.1517\/13543776.2016.1111872.","journal-title":"Expert Opin Ther Pat"},{"issue":"13\u201314","key":"3562_CR6","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.intimp.2003.08.007","volume":"3","author":"FA Fitzpatrick","year":"2003","unstructured":"Fitzpatrick FA, Wheeler R. The immunopharmacology of paclitaxel (Taxol\u00ae), docetaxel (Taxotere\u00ae), and related agents. Int Immunopharmacol. 2003;3(13\u201314):1699\u2013714. https:\/\/doi.org\/10.1016\/j.intimp.2003.08.007.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"3562_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/CAD.0b013e3280113338","volume":"18","author":"FK Engels","year":"2007","unstructured":"Engels FK, Mathot RAA, Verweij J. Alternative drug formulations of docetaxel: a review. Anticancer Drugs. 2007;18(2):95\u2013103. https:\/\/doi.org\/10.1097\/CAD.0b013e3280113338.","journal-title":"Anticancer Drugs"},{"issue":"4","key":"3562_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3332\/ecancer.2010.202","volume":"15","author":"M Hart","year":"2010","unstructured":"Hart M, Acott S. Physical and chemical stability of Taxotere\u00ae (docetaxel) one-vial (20 mg\/ml) infusion solution following refrigerated storage. Ecancermedicalscience. 2010;15(4):202. https:\/\/doi.org\/10.3332\/ecancer.2010.202.","journal-title":"Ecancermedicalscience"},{"key":"3562_CR9","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.2147\/IJN.S164518","volume":"13","author":"MF Sohail","year":"2018","unstructured":"Sohail MF, Rehman M, Sarwar HS, Naveed S, Qureshi OS, Bukhari NI, et al. Advancements in the oral delivery of docetaxel: challenges, current state-of-the-art and future trends. Int J Nanomedicine. 2018;13:3145\u201361. https:\/\/doi.org\/10.2147\/IJN.S164518.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"3562_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2008.04.019","volume":"129","author":"Y Qiu","year":"2008","unstructured":"Qiu Y, Gao Y, Hu K, Li F. Enhancement of skin permeation of docetaxel: a novel approach combining microneedle and elastic liposomes. J Control Release. 2008;129(2):144\u201350. https:\/\/doi.org\/10.1016\/j.jconrel.2008.04.019.","journal-title":"J Control Release"},{"issue":"42","key":"3562_CR11","doi-asserted-by":"publisher","first-page":"26161","DOI":"10.1039\/C7RA03180G","volume":"7","author":"L Zhang","year":"2017","unstructured":"Zhang L, Shen Y, Qiu L. Loading docetaxel in \u03b2-cyclodextrin-based micelles for enhanced oral chemotherapy through inhibition of P-glycoprotein mediated efflux transport. RSC Adv. 2017;7(42):26161\u20139. https:\/\/doi.org\/10.1039\/C7RA03180G.","journal-title":"RSC Adv"},{"issue":"6","key":"3562_CR12","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00280-014-2602-x","volume":"74","author":"D Mahalingam","year":"2014","unstructured":"Mahalingam D, Nemunaitis JJ, Malik L, Sarantopoulos J, Weitman S, Sankhala K, et al. Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014;74(6):1241\u201350. https:\/\/doi.org\/10.1007\/s00280-014-2602-x.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3562_CR13","doi-asserted-by":"publisher","unstructured":"Hu K, Feng, Cao. Enhanced oral bioavailability of docetaxel by lecithin nanoparticles: preparation, in vitro, and in vivo evaluation. IJN. 2012;3537. https:\/\/doi.org\/10.2147\/IJN.S32880.","DOI":"10.2147\/IJN.S32880"},{"issue":"7","key":"3562_CR14","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1021\/acs.molpharmaceut.6b00183","volume":"13","author":"K Raza","year":"2016","unstructured":"Raza K, Kumar D, Kiran C, Kumar M, Guru SK, Kumar P, et al. Conjugation of docetaxel with multiwalled carbon nanotubes and codelivery with piperine: implications on pharmacokinetic profile and anticancer activity. Mol Pharm. 2016;13(7):2423\u201332. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00183.","journal-title":"Mol Pharm"},{"issue":"1","key":"3562_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ijpharm.2015.09.016","volume":"495","author":"K Raza","year":"2015","unstructured":"Raza K, Thotakura N, Kumar P, Joshi M, Bhushan S, Bhatia A, et al. C 60 -fullerenes for delivery of docetaxel to breast cancer cells: a promising approach for enhanced efficacy and better pharmacokinetic profile. Int J Pharm. 2015;495(1):551\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.09.016.","journal-title":"Int J Pharm"},{"issue":"5","key":"3562_CR16","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1021\/bm100073s","volume":"11","author":"AS Mikhail","year":"2010","unstructured":"Mikhail AS, Allen C. Poly(ethylene glycol)- b -poly(\u03b5-caprolactone) micelles containing chemically conjugated and physically entrapped docetaxel: synthesis, characterization, and the influence of the drug on micelle morphology. Biomacromol. 2010;11(5):1273\u201380. https:\/\/doi.org\/10.1021\/bm100073s.","journal-title":"Biomacromol"},{"issue":"4","key":"3562_CR17","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1021\/mp4006968","volume":"11","author":"YW Naguib","year":"2014","unstructured":"Naguib YW, Rodriguez BL, Li X, Hursting SD, Williams RO, Cui Z. Solid lipid nanoparticle formulations of docetaxel prepared with high melting point triglycerides: in vitro and in vivo evaluation. Mol Pharm. 2014;11(4):1239\u201349. https:\/\/doi.org\/10.1021\/mp4006968.","journal-title":"Mol Pharm"},{"issue":"2","key":"3562_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0928-0987(00)00153-6","volume":"12","author":"JHM Schellens","year":"2000","unstructured":"Schellens JHM, Malingr\u00e9 MM, Kruijtzer CMF, Bardelmeijer HA, Van Tellingen O, Schinkel AH, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci. 2000;12(2):103\u201310. https:\/\/doi.org\/10.1016\/S0928-0987(00)00153-6.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"3562_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s40262-013-0040-2","volume":"52","author":"FE Stuurman","year":"2013","unstructured":"Stuurman FE, Nuijen B, Beijnen JH, Schellens JHM. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin Pharmacokinet. 2013;52(6):399\u2013414. https:\/\/doi.org\/10.1007\/s40262-013-0040-2.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3562_CR20","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","volume":"1","author":"CA Lipinski","year":"2004","unstructured":"Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol. 2004;1(4):337\u201341. https:\/\/doi.org\/10.1016\/j.ddtec.2004.11.007.","journal-title":"Drug Discov Today Technol"},{"issue":"4","key":"3562_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/j.1747-0285.2011.01170.x","volume":"78","author":"W Fayad","year":"2011","unstructured":"Fayad W, Rickardson L, Haglund C, Olofsson MH, D\u2019Arcy P, Larsson R, et al. Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties. Chem Biol Drug Des. 2011;78(4):547\u201357. https:\/\/doi.org\/10.1111\/j.1747-0285.2011.01170.x.","journal-title":"Chem Biol Drug Des"},{"issue":"11","key":"3562_CR22","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.3109\/03639045.2015.1014818","volume":"41","author":"SM Lim","year":"2015","unstructured":"Lim SM, Pang ZW, Tan HY, Shaikh M, Adinarayana G, Garg S. Enhancement of docetaxel solubility using binary and ternary solid dispersion systems. Drug Dev Ind Pharm. 2015;41(11):1847\u201355. https:\/\/doi.org\/10.3109\/03639045.2015.1014818.","journal-title":"Drug Dev Ind Pharm"},{"issue":"5","key":"3562_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.clpt.2004.01.001","volume":"75","author":"F Engels","year":"2004","unstructured":"Engels F. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther. 2004;75(5):448\u201354. https:\/\/doi.org\/10.1016\/j.clpt.2004.01.001.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3562_CR24","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1097\/00008571-199810000-00004","volume":"8","author":"M Shou","year":"1998","unstructured":"Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenet Genomics. 1998;8(5):391.","journal-title":"Pharmacogenet Genomics"},{"key":"3562_CR25","doi-asserted-by":"publisher","unstructured":"Lai Y. P-glycoprotein (P-gp\/MDR1)\/ABCB1. In: Transporters in drug discovery and development [Internet]. Elsevier; 2013 [cited 2024 Dec 5]. p. 147\u2013259. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9781907568213500026. https:\/\/doi.org\/10.1533\/9781908818287.147.","DOI":"10.1533\/9781908818287.147"},{"issue":"7","key":"3562_CR26","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1021\/cr9000226","volume":"109","author":"PDW Eckford","year":"2009","unstructured":"Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109(7):2989\u20133011. https:\/\/doi.org\/10.1021\/cr9000226.","journal-title":"Chem Rev"},{"issue":"4","key":"3562_CR27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1043-6618(03)00158-0","volume":"48","author":"M Varma","year":"2003","unstructured":"Varma M. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res. 2003;48(4):347\u201359. https:\/\/doi.org\/10.1016\/S1043-6618(03)00158-0.","journal-title":"Pharmacol Res"},{"issue":"13\u201314","key":"3562_CR28","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.addr.2013.09.018","volume":"65","author":"S Kunjachan","year":"2013","unstructured":"Kunjachan S, Rychlik B, Storm G, Kiessling F, Lammers T. Multidrug resistance: physiological principles and nanomedical solutions. Adv Drug Deliv Rev. 2013;65(13\u201314):1852\u201365. https:\/\/doi.org\/10.1016\/j.addr.2013.09.018.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"3562_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/10408347.2018.1456315","volume":"48","author":"GH Da Silva","year":"2018","unstructured":"Da Silva GH, Fernandes MA, Trevizan LNF, De Lima FT, Eloy JO, Chorilli M. A critical review of properties and analytical methods for the determination of docetaxel in biological and pharmaceutical matrices. Crit Rev Anal Chem. 2018;48(6):517\u201327. https:\/\/doi.org\/10.1080\/10408347.2018.1456315.","journal-title":"Crit Rev Anal Chem"},{"key":"3562_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2013.04.020","author":"K Thanki","year":"2013","unstructured":"Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J Control Release. 2013. https:\/\/doi.org\/10.1016\/j.jconrel.2013.04.020.","journal-title":"J Control Release"},{"issue":"7","key":"3562_CR31","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","volume":"18","author":"RW Robey","year":"2018","unstructured":"Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452\u201364. https:\/\/doi.org\/10.1038\/s41568-018-0005-8.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"3562_CR32","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1111\/cts.13003","volume":"14","author":"BS Moon","year":"2021","unstructured":"Moon BS, Park HS, Sunwoo J, Lee I, Kim A, Moon SJ, et al. Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography. Clinical Translational Sci. 2021;14(5):1747\u201355. https:\/\/doi.org\/10.1111\/cts.13003.","journal-title":"Clinical Translational Sci"},{"key":"3562_CR33","unstructured":"Daehwa Pharm\u2019s Oral Paclitaxel (Liporaxel) Approved in China for Gastric Cancer Treatment. 2025 Sep 26 [cited 2025 Oct 28]. Available from: https:\/\/trial.medpath.com\/news\/cb588b7632ba3c86\/daehwa-pharm-s-liporaxel-wins-chinese-approval-to-treat-gastric-cancer-pharma-article-kbr."},{"issue":"5","key":"3562_CR34","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/annonc\/mdy055","volume":"29","author":"YK Kang","year":"2018","unstructured":"Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018;29(5):1220\u20136. https:\/\/doi.org\/10.1093\/annonc\/mdy055.","journal-title":"Ann Oncol"},{"issue":"12","key":"3562_CR35","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1158\/1535-7163.MCT-07-0261","volume":"6","author":"JW Hong","year":"2007","unstructured":"Hong JW, Lee IH, Kwak YH, Park YT, Sung HC, Kwon IC, et al. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther. 2007;6(12):3239\u201347. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0261.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3562_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/aps.2016.105","volume":"38","author":"Y Jang","year":"2017","unstructured":"Jang Y, Chung HJ, Hong JW, Yun CW, Chung H. Absorption mechanism of DHP107, an oral paclitaxel formulation that forms a hydrated lipidic sponge phase. Acta Pharmacol Sin. 2017;38(1):133\u201345. https:\/\/doi.org\/10.1038\/aps.2016.105.","journal-title":"Acta Pharmacol Sin"},{"key":"3562_CR37","unstructured":"Scott R. Oral liporaxel may be superior to intravenous in advanced gastric cancer | CURE. oral liporaxel may be superior to intravenous in advanced gastric cancer | CURE [Internet]. 2025 Jan 27 [cited 2025 Oct 28]. Available from: https:\/\/www.curetoday.com\/view\/oral-liporaxel-may-be-superior-to-intravenous-in-advanced-gastric-cancer."},{"issue":"1\u20132","key":"3562_CR38","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijpharm.2017.04.061","volume":"526","author":"A Di Martino","year":"2017","unstructured":"Di Martino A, Guselnikova OA, Trusova ME, Postnikov PS, Sedlarik V. Organic-inorganic hybrid nanoparticles controlled delivery system for anticancer drugs. Int J Pharm. 2017;526(1\u20132):380\u201390. https:\/\/doi.org\/10.1016\/j.ijpharm.2017.04.061.","journal-title":"Int J Pharm"},{"key":"3562_CR39","unstructured":"Hyundai ADM Bio Showcases Innovative Oral Chemotherapy OTX-M at Biotech Showcase 2025. 2025 Jan 23 [cited 2025 Oct 21]. Available from: https:\/\/biopharmaapac.com\/news\/18\/5855\/hyundai-adm-bio-showcases-innovative-oral-chemotherapy-otx-m-at-biotech-showcase-2025.html."},{"key":"3562_CR40","unstructured":"Hyundai ADM Unveils a \u201cNew Paradigm in Cancer Treatment\u201d - Preclinical Study Shows Promise for Continuous Oral Chemotherapy with Lowered Side Effects Risks. 2025 Jan 22 [cited 2025 Oct 24]. Available from: https:\/\/www.prnewswire.com\/news-releases\/hyundai-adm-unveils-a-new-paradigm-in-cancer-treatment---preclinical-study-shows-promise-for-continuous-oral-chemotherapy-with-lowered-side-effects-risks-302357059.html."},{"issue":"3","key":"3562_CR41","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ejpb.2013.06.008","volume":"85","author":"C Xie","year":"2013","unstructured":"Xie C, Chang J, Hao XD, Yu JM, Liu HR, Sun X. Mitochondrial-targeted prodrug cancer therapy using a rhodamine B labeled fluorinated docetaxel. Eur J Pharm Biopharm. 2013;85(3):541\u20139. https:\/\/doi.org\/10.1016\/j.ejpb.2013.06.008.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"3562_CR42","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1039\/C8BM00947C","volume":"7","author":"W Cui","year":"2019","unstructured":"Cui W, Zhang S, Zhao H, Luo C, Sun B, Li Z, et al. Formulating a single thioether-bridged oleate prodrug into a self-nanoemulsifying drug delivery system to facilitate oral absorption of docetaxel. Biomater Sci. 2019;7(3):1117\u201331. https:\/\/doi.org\/10.1039\/C8BM00947C.","journal-title":"Biomater Sci"},{"issue":"4","key":"3562_CR43","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.bmcl.2017.07.041","volume":"28","author":"F Jing","year":"2018","unstructured":"Jing F, Guo Q, Xu W, Qu H, Sui Z. Docetaxel prodrug self-assembled nanosystem: synthesis, formulation and cytotoxicity. Bioorg Med Chem Lett. 2018;28(4):826\u201330. https:\/\/doi.org\/10.1016\/j.bmcl.2017.07.041.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"3562_CR44","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.3390\/molecules23051161","volume":"23","author":"P Saokham","year":"2018","unstructured":"Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of cyclodextrins and drug\/cyclodextrin complexes. Molecules. 2018;23(5):1161. https:\/\/doi.org\/10.3390\/molecules23051161.","journal-title":"Molecules"},{"issue":"6","key":"3562_CR45","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/pharmaceutics12060544","volume":"12","author":"M Wang","year":"2020","unstructured":"Wang M, You SK, Lee HK, Han MG, Lee HM, Pham TMA, et al. Development and evaluation of docetaxel-phospholipid complex loaded self-microemulsifying drug delivery system: optimization and in vitro\/ex vivo studies. Pharmaceutics. 2020;12(6):544. https:\/\/doi.org\/10.3390\/pharmaceutics12060544.","journal-title":"Pharmaceutics"},{"issue":"2","key":"3562_CR46","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/03639045.2021.1879840","volume":"47","author":"BR Giri","year":"2021","unstructured":"Giri BR, Lee J, Lim DY, Kim DW. Docetaxel\/dimethyl-\u03b2-cyclodextrin inclusion complexes: preparation, in vitro evaluation and physicochemical characterization. Drug Dev Ind Pharm. 2021;47(2):319\u201328. https:\/\/doi.org\/10.1080\/03639045.2021.1879840.","journal-title":"Drug Dev Ind Pharm"},{"issue":"11","key":"3562_CR47","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1039\/D0RA09720A","volume":"11","author":"XY Chen","year":"2021","unstructured":"Chen XY, Yang HW, Chi SM, Yue LL, Ruan Q, Lei Z, et al. Solubility and biological activity enhancement of docetaxel via formation of inclusion complexes with three alkylenediamine-modified \u03b2-cyclodextrins. RSC Adv. 2021;11(11):6292\u2013303. https:\/\/doi.org\/10.1039\/D0RA09720A.","journal-title":"RSC Adv"},{"issue":"4","key":"3562_CR48","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/CAD.0b013e328329977f","volume":"20","author":"S Miettinen","year":"2009","unstructured":"Miettinen S, Gr\u00e8nman S, Ylikomi T. Inhibition of P-glycoprotein-mediated docetaxel efflux sensitizes ovarian cancer cells to concomitant docetaxel and SN-38 exposure. Anticancer Drugs. 2009;20(4):267\u201376. https:\/\/doi.org\/10.1097\/CAD.0b013e328329977f.","journal-title":"Anticancer Drugs"},{"key":"3562_CR49","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejps.2018.12.016","volume":"129","author":"Y Wei","year":"2019","unstructured":"Wei Y, Zhou S, Hao T, Zhang J, Gao Y, Qian S. Further enhanced dissolution and oral bioavailability of docetaxel by coamorphization with a natural P-gp inhibitor myricetin. Eur J Pharm Sci. 2019;129:21\u201330. https:\/\/doi.org\/10.1016\/j.ejps.2018.12.016.","journal-title":"Eur J Pharm Sci"},{"key":"3562_CR50","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ejps.2017.02.009","volume":"101","author":"T Hao","year":"2017","unstructured":"Hao T, Ling Y, Wu M, Shen Y, Gao Y, Liang S, et al. Enhanced oral bioavailability of docetaxel in rats combined with myricetin: in situ and in vivo evidences. Eur J Pharm Sci. 2017;101:71\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2017.02.009.","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"3562_CR51","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.ejca.2004.01.024","volume":"40","author":"EM Kemper","year":"2004","unstructured":"Kemper EM, Verheij M, Boogerd W, Beijnen JH, Van Tellingen O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur J Cancer. 2004;40(8):1269\u201374. https:\/\/doi.org\/10.1016\/j.ejca.2004.01.024.","journal-title":"Eur J Cancer"},{"issue":"3","key":"3562_CR52","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/mabi.201500317","volume":"16","author":"Y Guo","year":"2016","unstructured":"Guo Y, Zhang P, Zhao Q, Wang K, Luan Y. Reduction-sensitive polymeric micelles based on docetaxel-polymer conjugates via disulfide linker for efficient cancer therapy. Macromol Biosci. 2016;16(3):420\u201331. https:\/\/doi.org\/10.1002\/mabi.201500317.","journal-title":"Macromol Biosci"},{"issue":"1\u20132","key":"3562_CR53","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijpharm.2013.04.020","volume":"451","author":"F Liu","year":"2013","unstructured":"Liu F, Feng L, Zhang L, Zhang X, Zhang N. Synthesis, characterization and antitumor evaluation of CMCS\u2013DTX conjugates as novel delivery platform for docetaxel. Int J Pharm. 2013;451(1\u20132):41\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2013.04.020.","journal-title":"Int J Pharm"},{"issue":"2","key":"3562_CR54","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3390\/ma8020379","volume":"8","author":"Y Liang","year":"2015","unstructured":"Liang Y, Su Z, Yao Y, Zhang N. Preparation of pH sensitive pluronic-docetaxel conjugate micelles to balance the stability and controlled release issues. Materials. 2015;8(2):379\u201391. https:\/\/doi.org\/10.3390\/ma8020379.","journal-title":"Materials"},{"key":"3562_CR55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ejps.2018.03.028","volume":"118","author":"L Ruiz-Gat\u00f3n","year":"2018","unstructured":"Ruiz-Gat\u00f3n L, Espuelas S, Larra\u00f1eta E, Reviakine I, Yate LA, Irache JM. Pegylated poly(anhydride) nanoparticles for oral delivery of docetaxel. Eur J Pharm Sci. 2018;118:165\u201375. https:\/\/doi.org\/10.1016\/j.ejps.2018.03.028.","journal-title":"Eur J Pharm Sci"},{"key":"3562_CR56","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.colsurfb.2018.11.077","volume":"175","author":"JMR Albano","year":"2019","unstructured":"Albano JMR, Ribeiro LNDM, Couto VM, Barbosa Messias M, Rodrigues Da Silva GH, Breitkreitz MC, et al. Rational design of polymer-lipid nanoparticles for docetaxel delivery. Colloids Surf B Biointerfaces. 2019;175:56\u201364. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.11.077.","journal-title":"Colloids Surf B Biointerfaces"},{"key":"3562_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/150478","volume":"2013","author":"S Saremi","year":"2013","unstructured":"Saremi S, Dinarvand R, Kebriaeezadeh A, Ostad SN, Atyabi F. Enhanced oral delivery of docetaxel using thiolated chitosan nanoparticles: preparation, in vitro and in vivo studies. Biomed Res Int. 2013;2013:1\u20138. https:\/\/doi.org\/10.1155\/2013\/150478.","journal-title":"Biomed Res Int"},{"issue":"4","key":"3562_CR58","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1021\/acs.bioconjchem.8b00059","volume":"29","author":"Y Guo","year":"2018","unstructured":"Guo Y, Zhao S, Qiu H, Wang T, Zhao Y, Han M, et al. Shape of nanoparticles as a design parameter to improve docetaxel antitumor efficacy. Bioconjug Chem. 2018;29(4):1302\u201311. https:\/\/doi.org\/10.1021\/acs.bioconjchem.8b00059.","journal-title":"Bioconjug Chem"},{"issue":"43","key":"3562_CR59","doi-asserted-by":"publisher","first-page":"17498","DOI":"10.1073\/pnas.1313839110","volume":"110","author":"S Attili-Qadri","year":"2013","unstructured":"Attili-Qadri S, Karra N, Nemirovski A, Schwob O, Talmon Y, Nassar T, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Natl Acad Sci U S A. 2013;110(43):17498\u2013503. https:\/\/doi.org\/10.1073\/pnas.1313839110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3562_CR60","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3109\/10837450.2014.971374","volume":"21","author":"AS Jain","year":"2016","unstructured":"Jain AS, Makhija DT, Goel PN, Shah SM, Nikam Y, Gude RP, et al. Docetaxel in cationic lipid nanocapsules for enhanced in vivo activity. Pharm Dev Technol. 2016;21(1):76\u201385. https:\/\/doi.org\/10.3109\/10837450.2014.971374.","journal-title":"Pharm Dev Technol"},{"key":"3562_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2025.103766","author":"LDQC Silva","year":"2025","unstructured":"Silva LDQC, Raspantini GL, Abriata JP, Luiz MT, De Sousa ACC, Moreira TDS, et al. PLGA\/TPGS nanoparticles for docetaxel delivery: the pegylation effect on nanoparticle physicochemical properties and uptake and cytotoxicity in prostate cancer cells. J Pharm Sci. 2025. https:\/\/doi.org\/10.1016\/j.xphs.2025.103766.","journal-title":"J Pharm Sci"},{"issue":"2","key":"3562_CR62","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz Y. Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117\u201334. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020.","journal-title":"J Control Release"},{"issue":"5","key":"3562_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09394","volume":"8","author":"H Nsairat","year":"2022","unstructured":"Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022;8(5):e09394. https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09394.","journal-title":"Heliyon"},{"key":"3562_CR64","doi-asserted-by":"publisher","unstructured":"Pereira S, Egbu R, Jannati G, Al-Jamal WT. Docetaxel-loaded liposomes: the effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int J Pharm. 2016;514(1):150\u20139. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.06.057. (In Honour of Professor Alexander T. Florence).","DOI":"10.1016\/j.ijpharm.2016.06.057"},{"issue":"1","key":"3562_CR65","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.supflu.2010.02.005","volume":"54","author":"S Naik","year":"2010","unstructured":"Naik S, Patel D, Surti N, Misra A. Preparation of PEGylated liposomes of docetaxel using supercritical fluid technology. J Supercrit Fluids. 2010;54(1):110\u20139. https:\/\/doi.org\/10.1016\/j.supflu.2010.02.005.","journal-title":"J Supercrit Fluids"},{"key":"3562_CR66","doi-asserted-by":"publisher","unstructured":"Mathematical models of drug release. In: Strategies to modify the drug release from pharmaceutical systems. Elsevier; 2015. p. 63\u201386. https:\/\/doi.org\/10.1016\/B978-0-08-100092-2.00005-9","DOI":"10.1016\/B978-0-08-100092-2.00005-9"},{"key":"3562_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2024.124091","volume":"656","author":"M Dacos","year":"2024","unstructured":"Dacos M, Immordino B, Diroff E, Sicard G, Kosta A, Rodallec A, et al. Pegylated liposome encapsulating docetaxel using microfluidic mixing technique: process optimization and results in breast cancer models. Int J Pharm. 2024;656:124091. https:\/\/doi.org\/10.1016\/j.ijpharm.2024.124091.","journal-title":"Int J Pharm"},{"issue":"3","key":"3562_CR68","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00280-012-2048-y","volume":"71","author":"JF Deeken","year":"2013","unstructured":"Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, et al. A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies. Cancer Chemother Pharmacol. 2013;71(3):627\u201333. https:\/\/doi.org\/10.1007\/s00280-012-2048-y.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3562_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","volume":"24","author":"VP Torchilin","year":"2006","unstructured":"Torchilin VP. Micellar nanocarriers: pharmaceutical perspectives. Pharm Res. 2006;24(1):1\u201316. https:\/\/doi.org\/10.1007\/s11095-006-9132-0.","journal-title":"Pharm Res"},{"issue":"1","key":"3562_CR70","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/10717544.2020.1718245","volume":"27","author":"F Gong","year":"2020","unstructured":"Gong F, Wang R, Zhu Z, Duan J, Teng X, Cui ZK. Drug-interactive mPEG- b -PLA-Phe(Boc) micelles enhance the tolerance and anti-tumor efficacy of docetaxel. Drug Delivery. 2020;27(1):238\u201347. https:\/\/doi.org\/10.1080\/10717544.2020.1718245.","journal-title":"Drug Delivery"},{"key":"3562_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ejpb.2017.11.006","volume":"123","author":"CY Su","year":"2018","unstructured":"Su CY, Liu JJ, Ho YS, Huang YY, Chang VHS, Liu DZ, et al. Development and characterization of docetaxel-loaded lecithin-stabilized micellar drug delivery system (L sb MDDs) for improving the therapeutic efficacy and reducing systemic toxicity. Eur J Pharm Biopharm. 2018;123:9\u201319. https:\/\/doi.org\/10.1016\/j.ejpb.2017.11.006.","journal-title":"Eur J Pharm Biopharm"},{"key":"3562_CR72","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.jconrel.2017.03.008","volume":"252","author":"Y Singh","year":"2017","unstructured":"Singh Y, Meher JG, Raval K, Khan FA, Chaurasia M, Jain NK, et al. Nanoemulsion: concepts, development and applications in drug delivery. J Control Release. 2017;252:28\u201349. https:\/\/doi.org\/10.1016\/j.jconrel.2017.03.008.","journal-title":"J Control Release"},{"issue":"2","key":"3562_CR73","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13205-014-0214-0","volume":"5","author":"M Jaiswal","year":"2015","unstructured":"Jaiswal M, Dudhe R, Sharma PK. Nanoemulsion: an advanced mode of drug delivery system. 3 Biotech. 2015;5(2):123\u20137. https:\/\/doi.org\/10.1007\/s13205-014-0214-0.","journal-title":"3 Biotech"},{"issue":"2","key":"3562_CR74","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3109\/10717544.2014.920430","volume":"23","author":"P Verma","year":"2016","unstructured":"Verma P, Meher JG, Asthana S, Pawar VK, Chaurasia M, Chourasia MK. Perspectives of nanoemulsion assisted oral delivery of docetaxel for improved chemotherapy of cancer. Drug Deliv. 2016;23(2):479\u201388. https:\/\/doi.org\/10.3109\/10717544.2014.920430.","journal-title":"Drug Deliv"},{"issue":"3","key":"3562_CR75","doi-asserted-by":"publisher","first-page":"958","DOI":"10.3109\/10717544.2014.923068","volume":"23","author":"S Ganta","year":"2016","unstructured":"Ganta S, Singh A, Rawal Y, Cacaccio J, Patel NR, Kulkarni P, et al. Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv. 2016;23(3):958\u201370. https:\/\/doi.org\/10.3109\/10717544.2014.923068.","journal-title":"Drug Deliv"},{"issue":"15","key":"3562_CR76","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.3390\/molecules26154481","volume":"26","author":"M Cheng","year":"2021","unstructured":"Cheng M, Liu Q, Gan T, Fang Y, Yue P, Sun Y, et al. Nanocrystal-loaded micelles for the enhanced in vivo circulation of docetaxel. Molecules. 2021;26(15):4481. https:\/\/doi.org\/10.3390\/molecules26154481.","journal-title":"Molecules"},{"key":"3562_CR77","doi-asserted-by":"publisher","unstructured":"Joseph E, Singhvi G. Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. In: Nanomaterials for drug delivery and therapy. Elsevier; 2019. p. 91\u2013116. https:\/\/doi.org\/10.1016\/B978-0-12-816505-8.00007-2.","DOI":"10.1016\/B978-0-12-816505-8.00007-2"},{"issue":"16","key":"3562_CR78","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.2217\/nnm.15.73","volume":"10","author":"Y Lu","year":"2015","unstructured":"Lu Y, Chen Y, Gemeinhart RA, Wu W, Li T. Developing nanocrystals for cancer treatment. Nanomedicine (Lond). 2015;10(16):2537\u201352. https:\/\/doi.org\/10.2217\/nnm.15.73.","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"3562_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1499","volume":"10","author":"X Miao","year":"2018","unstructured":"Miao X, Yang W, Feng T, Lin J, Huang P. Drug nanocrystals for cancer therapy. WIREs Nanomed Nanobiotechnol. 2018;10(3):e1499. https:\/\/doi.org\/10.1002\/wnan.1499.","journal-title":"WIREs Nanomed Nanobiotechnol"},{"issue":"10","key":"3562_CR80","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1166\/jbn.2015.2158","volume":"11","author":"VK Pawar","year":"2015","unstructured":"Pawar VK, Gupta S, Singh Y, Meher JG, Sharma K, Singh P, et al. Pluronic F-127 stabilised docetaxel nanocrystals improve apoptosis by mitochondrial depolarization in breast cancer cells: pharmacokinetics and toxicity assessment. J Biomed Nanotechnol. 2015;11(10):1747\u201363. https:\/\/doi.org\/10.1166\/jbn.2015.2158.","journal-title":"J Biomed Nanotechnol"},{"key":"3562_CR81","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/DDDT.S122984","volume":"11","author":"JS Choi","year":"2016","unstructured":"Choi JS, Park JS. Development of docetaxel nanocrystals surface modified with transferrin for tumor targeting. Drug Des Discov Ther. 2016;11:17\u201326. https:\/\/doi.org\/10.2147\/DDDT.S122984.","journal-title":"Drug Des Discov Ther"},{"issue":"45","key":"3562_CR82","doi-asserted-by":"publisher","first-page":"26777","DOI":"10.1039\/D0RA03491F","volume":"10","author":"Y Duan","year":"2020","unstructured":"Duan Y, Dhar A, Patel C, Khimani M, Neogi S, Sharma P, et al. A brief review on solid lipid nanoparticles: part and parcel of contemporary drug delivery systems. RSC Adv. 2020;10(45):26777\u201391. https:\/\/doi.org\/10.1039\/D0RA03491F.","journal-title":"RSC Adv"},{"issue":"7","key":"3562_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2020.587997","volume":"30","author":"S Scioli Montoto","year":"2020","unstructured":"Scioli Montoto S, Muraca G, Ruiz ME. Solid lipid nanoparticles for drug delivery: pharmacological and biopharmaceutical aspects. Front Mol Biosci. 2020;30(7):587997. https:\/\/doi.org\/10.3389\/fmolb.2020.587997.","journal-title":"Front Mol Biosci"},{"issue":"3","key":"3562_CR84","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3390\/pharmaceutics15030831","volume":"15","author":"J German-Cort\u00e9s","year":"2023","unstructured":"German-Cort\u00e9s J, Vilar-Hern\u00e1ndez M, Rafael D, Abasolo I, Andrade F. Solid lipid nanoparticles: multitasking nano-carriers for cancer treatment. Pharmaceutics. 2023;15(3):831. https:\/\/doi.org\/10.3390\/pharmaceutics15030831.","journal-title":"Pharmaceutics"},{"issue":"45","key":"3562_CR85","doi-asserted-by":"publisher","first-page":"1903156","DOI":"10.1002\/smll.201903156","volume":"15","author":"DL Pink","year":"2019","unstructured":"Pink DL, Loruthai O, Ziolek RM, Wasutrasawat P, Terry AE, Lawrence MJ, et al. On the structure of solid lipid nanoparticles. Small. 2019;15(45):1903156. https:\/\/doi.org\/10.1002\/smll.201903156.","journal-title":"Small"},{"issue":"1","key":"3562_CR86","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s12951-020-00604-7","volume":"18","author":"MCO Da Rocha","year":"2020","unstructured":"Da Rocha MCO, Da Silva PB, Radicchi MA, Andrade BYG, De Oliveira JV, Venus T, et al. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells. J Nanobiotechnol. 2020;18(1):43. https:\/\/doi.org\/10.1186\/s12951-020-00604-7.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"3562_CR87","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/13543776.2020.1720649","volume":"30","author":"R Paliwal","year":"2020","unstructured":"Paliwal R, Paliwal SR, Kenwat R, Kurmi BD, Sahu MK. Solid lipid nanoparticles: a review on recent perspectives and patents. Expert Opin Ther Pat. 2020;30(3):179\u201394. https:\/\/doi.org\/10.1080\/13543776.2020.1720649.","journal-title":"Expert Opin Ther Pat"},{"key":"3562_CR88","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejpb.2023.05.020","volume":"189","author":"S Korake","year":"2023","unstructured":"Korake S, Bothiraja C, Pawar A. Design, development, and in-vitro\/in-vivo evaluation of docetaxel-loaded PEGylated solid lipid nanoparticles in prostate cancer therapy. Eur J Pharm Biopharm. 2023;189:15\u201327. https:\/\/doi.org\/10.1016\/j.ejpb.2023.05.020.","journal-title":"Eur J Pharm Biopharm"},{"key":"3562_CR89","doi-asserted-by":"publisher","first-page":"8091","DOI":"10.2147\/IJN.S478964","volume":"19","author":"N Wathoni","year":"2024","unstructured":"Wathoni N, Suhandi C, Elamin K, Lesmana R, Hasan N, Mohammed A, et al. Advancements and challenges of nanostructured lipid carriers for wound healing applications. IJN. 2024;19:8091\u2013113. https:\/\/doi.org\/10.2147\/IJN.S478964.","journal-title":"IJN"},{"issue":"2","key":"3562_CR90","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/08982104.2019.1614055","volume":"30","author":"P Mathur","year":"2020","unstructured":"Mathur P, Sharma S, Rawal S, Patel B, Patel MM. Fabrication, optimization, and in vitro evaluation of docetaxel-loaded nanostructured lipid carriers for improved anticancer activity. J Liposome Res. 2020;30(2):182\u201396. https:\/\/doi.org\/10.1080\/08982104.2019.1614055.","journal-title":"J Liposome Res"},{"issue":"4","key":"3562_CR91","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00280-020-04048-6","volume":"85","author":"M Li","year":"2020","unstructured":"Li M, Pei J, Ma Z, Fu J, Chen F, Du S. Docetaxel-loaded ultrasmall nanostructured lipid carriers for cancer therapy: in vitro and in vivo evaluation. Cancer Chemother Pharmacol. 2020;85(4):731\u20139. https:\/\/doi.org\/10.1007\/s00280-020-04048-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"3562_CR92","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1039\/D1NA00293G","volume":"3","author":"R Dubey","year":"2021","unstructured":"Dubey R, Dutta D, Sarkar A, Chattopadhyay P. Functionalized carbon nanotubes: synthesis, properties and applications in water purification, drug delivery, and material and biomedical sciences. Nanoscale Adv. 2021;3(20):5722\u201344. https:\/\/doi.org\/10.1039\/D1NA00293G.","journal-title":"Nanoscale Adv"},{"key":"3562_CR93","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.2147\/IJN.S299448","volume":"16","author":"H Zare","year":"2021","unstructured":"Zare H, Ahmadi S, Ghasemi A, Ghanbari M, Rabiee N, Bagherzadeh M, et al. Carbon nanotubes: smart drug\/gene delivery carriers. Int J Nanomedicine. 2021;16:1681\u2013706. https:\/\/doi.org\/10.2147\/IJN.S299448.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"3562_CR94","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12951-021-01174-y","volume":"19","author":"L Tang","year":"2021","unstructured":"Tang L, Xiao Q, Mei Y, He S, Zhang Z, Wang R, et al. Insights on functionalized carbon nanotubes for cancer theranostics. J Nanobiotechnol. 2021;19(1):423. https:\/\/doi.org\/10.1186\/s12951-021-01174-y.","journal-title":"J Nanobiotechnol"},{"key":"3562_CR95","doi-asserted-by":"publisher","unstructured":"Wang L, Zhang, Zhang, Shi, Zhang, Zhang Z, et al. Synergistic enhancement of cancer therapy using a combination of docetaxel and photothermal ablation induced by single-walled carbon nanotubes. IJN. 2011;2641. https:\/\/doi.org\/10.2147\/IJN.S24167.","DOI":"10.2147\/IJN.S24167"},{"key":"3562_CR96","doi-asserted-by":"publisher","unstructured":"Singh RP, Sharma G, Sonali, Singh S, Kumar M, Pandey BL, et al. Vitamin E TPGS conjugated carbon nanotubes improved efficacy of docetaxel with safety for lung cancer treatment. Colloids Surf B Biointerfaces. 2016;141:429\u201342. https:\/\/doi.org\/10.1016\/j.colsurfb.2016.02.011.","DOI":"10.1016\/j.colsurfb.2016.02.011"},{"issue":"1","key":"3562_CR97","doi-asserted-by":"publisher","DOI":"10.1007\/s11671-010-9741-8","volume":"6","author":"H Chen","year":"2010","unstructured":"Chen H, Zheng Y, Tian G, Tian Y, Zeng X, Liu G, et al. Oral delivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy. Nanoscale Res Lett. 2010;6(1):4. https:\/\/doi.org\/10.1007\/s11671-010-9741-8.","journal-title":"Nanoscale Res Lett"},{"issue":"7","key":"3562_CR98","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s12272-018-1046-y","volume":"41","author":"JH Kim","year":"2018","unstructured":"Kim JH, Shin DH, Kim JS. Preparation, characterization, and pharmacokinetics of liposomal docetaxel for oral administration. Arch Pharm Res. 2018;41(7):765\u201375. https:\/\/doi.org\/10.1007\/s12272-018-1046-y.","journal-title":"Arch Pharm Res"},{"issue":"1\u20132","key":"3562_CR99","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ijpharm.2018.06.028","volume":"547","author":"JM Lee","year":"2018","unstructured":"Lee JM, Park H, Oh KT, Lee ES. pH-Responsive hyaluronated liposomes for docetaxel delivery. Int J Pharm. 2018;547(1\u20132):377\u201384. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.06.028.","journal-title":"Int J Pharm"},{"issue":"2","key":"3562_CR100","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijpharm.2011.09.045","volume":"421","author":"MS Muthu","year":"2011","unstructured":"Muthu MS, Kulkarni SA, Xiong J, Feng SS. Vitamin e TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cells. Int J Pharm. 2011;421(2):332\u201340. https:\/\/doi.org\/10.1016\/j.ijpharm.2011.09.045.","journal-title":"Int J Pharm"},{"issue":"25","key":"3562_CR101","doi-asserted-by":"publisher","first-page":"6972","DOI":"10.1016\/j.biomaterials.2014.04.099","volume":"35","author":"YJ Wang","year":"2014","unstructured":"Wang YJ, Chen LJ, Tan LW, Zhao Q, Luo F, Wei YQ, et al. PEG-PCL based micelle hydrogels as oral docetaxel delivery systems for breast cancer therapy. Biomaterials. 2014;35(25):6972\u201385. https:\/\/doi.org\/10.1016\/j.biomaterials.2014.04.099.","journal-title":"Biomaterials"},{"issue":"114","key":"3562_CR102","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.colsurfb.2013.09.010","volume":"1","author":"J Dou","year":"2014","unstructured":"Dou J, Zhang H, Liu X, Zhang M, Zhai G. Preparation and evaluation in vitro and in vivo of docetaxel loaded mixed micelles for oral administration. Colloids Surf B. 2014;1(114):20\u20137. https:\/\/doi.org\/10.1016\/j.colsurfb.2013.09.010.","journal-title":"Colloids Surf B"},{"issue":"9","key":"3562_CR103","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/molecules21091265","volume":"21","author":"A Hekmat","year":"2016","unstructured":"Hekmat A, Attar H, Seyf Kordi A, Iman M, Jaafari M. New oral formulation and in vitro evaluation of docetaxel-loaded nanomicelles. Molecules. 2016;21(9):1265. https:\/\/doi.org\/10.3390\/molecules21091265.","journal-title":"Molecules"},{"issue":"6","key":"3562_CR104","first-page":"41","volume":"8","author":"MH Alkhatib","year":"2017","unstructured":"Alkhatib MH, Alharbi SA, Mahassni SH. In vivo evaluation of the anticancer activity of the docetaxel incorporated into nanoemulsion based on orange oil. Pharmacophore. 2017;8(6):41\u20137.","journal-title":"Pharmacophore."},{"issue":"16","key":"3562_CR105","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.2217\/nnm-2016-0120","volume":"11","author":"SM Afzal","year":"2016","unstructured":"Afzal SM, Shareef MZ, Dinesh T, Kishan V. Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity. Nanomedicine. 2016;11(16):2171\u201384. https:\/\/doi.org\/10.2217\/nnm-2016-0120.","journal-title":"Nanomedicine"},{"issue":"2","key":"3562_CR106","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s13346-018-0526-4","volume":"9","author":"AA Asmawi","year":"2019","unstructured":"Asmawi AA, Salim N, Ngan CL, Ahmad H, Abdulmalek E, Masarudin MJ, et al. Excipient selection and aerodynamic characterization of nebulized lipid-based nanoemulsion loaded with docetaxel for lung cancer treatment. Drug Deliv Transl Res. 2019;9(2):543\u201354. https:\/\/doi.org\/10.1007\/s13346-018-0526-4.","journal-title":"Drug Deliv Transl Res"},{"issue":"3","key":"3562_CR107","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1021\/acs.molpharmaceut.7b00783","volume":"15","author":"SF Gad","year":"2018","unstructured":"Gad SF, Park J, Park JE, Fetih GN, Tous SS, Lee W, et al. Enhancing docetaxel delivery to multidrug-resistant cancer cells with albumin-coated nanocrystals. Mol Pharm. 2018;15(3):871\u201381. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00783.","journal-title":"Mol Pharm"},{"key":"3562_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2017.07.064","author":"J Choi","year":"2017","unstructured":"Choi J, Park J. Surface modification of docetaxel nanocrystals with HER2 antibody to enhance cell growth inhibition in breast cancer cells. Colloids Surf B Biointerfaces. 2017. https:\/\/doi.org\/10.1016\/j.colsurfb.2017.07.064.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"1","key":"3562_CR109","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/IJN.S56648","volume":"9","author":"HJ Cho","year":"2014","unstructured":"Cho HJ, Park JW, Yoon IS, Kim DD. Surface-modified solid lipid nanoparticles for oral delivery of docetaxel: Enhanced intestinal absorption and lymphatic uptake. Int J Nanomed. 2014;9(1):495\u2013504. https:\/\/doi.org\/10.2147\/IJN.S56648.","journal-title":"Int J Nanomed"},{"key":"3562_CR110","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jddst.2019.01.042","volume":"50","author":"SE Lee","year":"2019","unstructured":"Lee SE, Lee CD, Ahn JB, Kim DH, Lee JK, Lee JY, et al. Hyaluronic acid-coated solid lipid nanoparticles to overcome drug-resistance in tumor cells. J Drug Deliv Sci Technol. 2019;50:365\u201371. https:\/\/doi.org\/10.1016\/j.jddst.2019.01.042.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"3562_CR111","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1080\/03639045.2016.1220571","volume":"43","author":"LL Shi","year":"2017","unstructured":"Shi LL, Lu J, Cao Y, Liu JY, Zhang XX, Zhang H, et al. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel. Drug Dev Ind Pharm. 2017;43(5):839\u201346. https:\/\/doi.org\/10.1080\/03639045.2016.1220571.","journal-title":"Drug Dev Ind Pharm"},{"issue":"117","key":"3562_CR112","doi-asserted-by":"publisher","first-page":"96437","DOI":"10.1039\/c5ra14588k","volume":"5","author":"G Fang","year":"2015","unstructured":"Fang G, Tang B, Chao Y, Zhang Y, Xu H, Tang X. Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv. 2015;5(117):96437\u201347. https:\/\/doi.org\/10.1039\/c5ra14588k.","journal-title":"RSC Adv"},{"issue":"7","key":"3562_CR113","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1021\/acs.molpharmaceut.5b00081","volume":"12","author":"G Fang","year":"2015","unstructured":"Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, et al. Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study. Mol Pharm. 2015;12(7):2384\u201395. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.5b00081.","journal-title":"Mol Pharm"},{"issue":"4","key":"3562_CR114","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/08982104.2017.1370471","volume":"28","author":"J Varshosaz","year":"2018","unstructured":"Varshosaz J, Davoudi MA, Rasoul-Amini S. Docetaxel-loaded nanostructured lipid carriers functionalized with trastuzumab (Herceptin) for HER2-positive breast cancer cells. J Liposome Res. 2018;28(4):285\u201395. https:\/\/doi.org\/10.1080\/08982104.2017.1370471.","journal-title":"J Liposome Res"},{"key":"3562_CR115","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.polymer.2017.03.084","volume":"117","author":"F Hossein Panahi","year":"2017","unstructured":"Hossein Panahi F, Peighambardoust SJ, Davaran S, Salehi R. Development and characterization of PLA-mPEG copolymer containing iron nanoparticle-coated carbon nanotubes for controlled delivery of docetaxel. Polymer. 2017;117:117\u201331. https:\/\/doi.org\/10.1016\/j.polymer.2017.03.084.","journal-title":"Polymer"},{"issue":"12","key":"3562_CR116","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1166\/jbn.2014.1875","volume":"10","author":"S Arora","year":"2014","unstructured":"Arora S, Kumar R, Kaur H, Rayat CS, Kaur I, Arora SK, et al. Translocation and toxicity of docetaxel multi-walled carbon nanotube conjugates in mammalian breast cancer cells. J Biomed Nanotechnol. 2014;10(12):3601\u20139. https:\/\/doi.org\/10.1166\/jbn.2014.1875.","journal-title":"J Biomed Nanotechnol"},{"issue":"4","key":"3562_CR117","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/cncr.21227","volume":"104","author":"L Pusztai","year":"2005","unstructured":"Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, et al. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005;104(4):682\u201391. https:\/\/doi.org\/10.1002\/cncr.21227.","journal-title":"Cancer"},{"key":"3562_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/533304a","author":"H Ledford","year":"2016","unstructured":"Ledford H. Bankruptcy filing worries developers of nanoparticle cancer drugs. Nature. 2016. https:\/\/doi.org\/10.1038\/533304a.","journal-title":"Nature"},{"key":"3562_CR119","unstructured":"Conte C, d\u2019Angelo I, Miro A, Ungaro F, Quaglia F. PEGylated polyester-based nanoncologicals."},{"key":"3562_CR120","doi-asserted-by":"publisher","unstructured":"Ren K, Dusad A, Dong R, Quan L. Albumin as a delivery carrier for rheumatoid arthritis. J Nanomed Nanotechnol. 2013;4(4). https:\/\/doi.org\/10.4172\/2157-7439.1000176.","DOI":"10.4172\/2157-7439.1000176"},{"key":"3562_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.03.027","author":"B Louage","year":"2017","unstructured":"Louage B, De Wever O, Hennink WE, De Geest BG. Developments and future clinical outlook of taxane nanomedicines. J Control Release. 2017. https:\/\/doi.org\/10.1016\/j.jconrel.2017.03.027.","journal-title":"J Control Release"},{"key":"3562_CR122","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jconrel.2016.07.012","volume":"244","author":"Q Hu","year":"2016","unstructured":"Hu Q, Rijcken CJF, van Gaal E, Brundel P, Kostkova H, Etrych T, et al. Tailoring the physicochemical properties of core-crosslinked polymeric micelles for pharmaceutical applications. J Control Release. 2016;244:314\u201325. https:\/\/doi.org\/10.1016\/j.jconrel.2016.07.012.","journal-title":"J Control Release"},{"key":"3562_CR123","doi-asserted-by":"publisher","unstructured":"Walker S, Charbonneau F, Law S. Stability of docetaxel solution after dilution in ethanol and storage in vials and after dilution in normal saline and storage in bags. Can J Hosp Pharm. 2007;60(4). https:\/\/doi.org\/10.4212\/cjhp.v60i4.184.","DOI":"10.4212\/cjhp.v60i4.184"},{"issue":"17","key":"3562_CR124","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2146\/ajhp080482","volume":"66","author":"AA Eroles","year":"2009","unstructured":"Eroles AA, Bafalluy IM, Arnaiz JAS. Stability of docetaxel diluted to 0.3 or 0.9 mg\/mL with 0.9% sodium chloride injection and stored in polyolefin or glass containers. Am J Health Syst Pharm. 2009;66(17):1565\u20138. https:\/\/doi.org\/10.2146\/ajhp080482.","journal-title":"Am J Health Syst Pharm"},{"key":"3562_CR125","unstructured":"European Medicines Agency (EMA). Information for the package leaflet regarding polysorbates used as excipients in medicinal products for human use [EMA\/CHMP\/392097\/2023]. Amsterdam: European Medicines Agency; 2023. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf."},{"issue":"5","key":"3562_CR126","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clpt.2003.08.004","volume":"74","author":"A Tentije","year":"2003","unstructured":"Tentije A, Loos W, Verweij J, Baker S, Dinh K, Figg W, et al. Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches. Clin Pharmacol Ther. 2003;74(5):509\u201310. https:\/\/doi.org\/10.1016\/j.clpt.2003.08.004.","journal-title":"Clin Pharmacol Ther"},{"key":"3562_CR127","unstructured":"BeizrayTM (Docetaxel) injection | to be mixed with albumin [Internet]. 2025 Aug 1 [cited 2026 Aug 15]. Available from: https:\/\/beizray.us\/home\/."},{"key":"3562_CR128","unstructured":"Sun Q. Neutral pH compositions of Docetaxel and human serum albumin [Internet]. US11419842B2, 2022 [cited 2026 Aug 15]. Available from: https:\/\/patents.google.com\/patent\/US11419842B2\/en?oq=US11419842."},{"key":"3562_CR129","unstructured":"DOCIVYXTM \u2013 (docetaxel) injection [Internet]. [cited 2026 Aug 15]. Available from: https:\/\/docivyx.com\/."},{"key":"3562_CR130","unstructured":"Zhao WW, Thottathil JK, Smith D, Sun X, Dong X. Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use [Internet]. US10398785B2, 2019 [cited 2026 Aug 15]. Available from: https:\/\/patents.google.com\/patent\/US10398785B2\/en?oq=US10398785."},{"issue":"9","key":"3562_CR131","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.4161\/cbt.4.9.2052","volume":"4","author":"GD Kruh","year":"2005","unstructured":"Kruh GD. Ins and outs of taxanes. Cancer Biol Ther. 2005;4(9):1030\u20132. https:\/\/doi.org\/10.4161\/cbt.4.9.2052.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"3562_CR132","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000481339","volume":"13","author":"E El Rassy","year":"2018","unstructured":"El Rassy E, Ghosn M, Farhat F, Bakouny Z, Assi T, Chahine G, et al. Toxicities associated with docetaxel-based regimens in the adjuvant treatment of early-stage breast cancer: a multicenter prospective real-life experience. Breast Care (Basel). 2018;13(2):119\u201323. https:\/\/doi.org\/10.1159\/000481339.","journal-title":"Breast Care (Basel)"},{"issue":"6","key":"3562_CR133","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S0009-9236(96)90208-8","volume":"60","author":"ET Hellriegel","year":"1996","unstructured":"Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bioequivalence studies. Clin Pharmacol Ther. 1996;60(6):601\u20137. https:\/\/doi.org\/10.1016\/S0009-9236(96)90208-8.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"3562_CR134","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/cas.12647","volume":"106","author":"H Kenmotsu","year":"2015","unstructured":"Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci. 2015;106(5):497\u2013504. https:\/\/doi.org\/10.1111\/cas.12647.","journal-title":"Cancer Sci"},{"issue":"8","key":"3562_CR135","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1007\/s11095-006-9041-2","volume":"23","author":"X Cao","year":"2006","unstructured":"Cao X, Gibbs ST, Fang L, Miller HA, Landowski CP, Shin HC, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res. 2006;23(8):1675\u201386. https:\/\/doi.org\/10.1007\/s11095-006-9041-2.","journal-title":"Pharm Res"},{"key":"3562_CR136","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","volume":"244","author":"F Danhier","year":"2016","unstructured":"Danhier F. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244:108\u201321. https:\/\/doi.org\/10.1016\/j.jconrel.2016.11.015.","journal-title":"J Control Release"},{"issue":"13","key":"3562_CR137","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1158\/1078-0432.CCR-15-2548","volume":"22","author":"DD Von Hoff","year":"2016","unstructured":"Von Hoff DD, Mita MM, Ramanathan RK, Weiss GJ, Mita AC, LoRusso PM, et al. Phase I study of PSMA-targeted docetaxel-containing nanoparticle BIND-014 in patients with advanced solid tumors. Clin Cancer Res. 2016;22(13):3157\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2548.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3562_CR138","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","volume":"16","author":"R Bruno","year":"1998","unstructured":"Bruno R, Hille D, Riva A, Vivier N, Ten Bokkel Huinnink WW, Van Oosterom AT, et al. Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer. JCO. 1998;16(1):187\u201396. https:\/\/doi.org\/10.1200\/JCO.1998.16.1.187.","journal-title":"JCO"},{"issue":"10","key":"3562_CR139","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1001\/jamaoncol.2018.2168","volume":"4","author":"KA Autio","year":"2018","unstructured":"Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, et al. Safety and efficacy of BIND-014, a docetaxel nanoparticle targeting prostate-specific membrane antigen for patients with metastatic castration-resistant prostate cancer: a phase 2 clinical trial. JAMA Oncol. 2018;4(10):1344. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2168.","journal-title":"JAMA Oncol"},{"key":"3562_CR140","doi-asserted-by":"publisher","unstructured":"Kolhe P, Shah M, Rathore N, editors. Sterile product development: formulation, process, quality and regulatory considerations. Vol. 6. New York: Springer New York; 2013 (AAPS Advances in the Pharmaceutical Sciences Series). https:\/\/doi.org\/10.1007\/978-1-4614-7978-9.","DOI":"10.1007\/978-1-4614-7978-9"},{"key":"3562_CR141","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/9780470259818.ch4","volume-title":"Pharmaceutical manufacturing handbook","author":"J Agalloco","year":"2008","unstructured":"Agalloco J, Akers J. Sterile product manufacturing. In: Gad SC, editor. Pharmaceutical manufacturing handbook. 1st ed. Wiley; 2008. p. 97\u2013135. https:\/\/doi.org\/10.1002\/9780470259818.ch4.","edition":"1"},{"key":"3562_CR142","doi-asserted-by":"publisher","unstructured":"Nagarsenkar MS, Dhawan VV. Parenteral preparations. In: Remington. Elsevier; 2021. p. 577\u2013603. https:\/\/doi.org\/10.1016\/B978-0-12-820007-0.00029-5.","DOI":"10.1016\/B978-0-12-820007-0.00029-5"},{"issue":"2","key":"3562_CR143","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s13346-022-01223-5","volume":"13","author":"K Panchal","year":"2023","unstructured":"Panchal K, Katke S, Dash SK, Gaur A, Shinde A, Saha N, et al. An expanding horizon of complex injectable products: development and regulatory considerations. Drug Deliv Transl Res. 2023;13(2):433\u201372. https:\/\/doi.org\/10.1007\/s13346-022-01223-5.","journal-title":"Drug Deliv Transl Res"},{"key":"3562_CR144","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/978-1-4614-0554-2_23","volume-title":"Long acting injections and implants","author":"M Kastellorizios","year":"2012","unstructured":"Kastellorizios M, Burgess DJ. In vitro drug release testing and in vivo\/in vitro correlation for long acting implants and injections. In: Wright JC, Burgess DJ, editors. Long acting injections and implants. Boston: Springer US; 2012. p. 475\u2013503. https:\/\/doi.org\/10.1007\/978-1-4614-0554-2_23."},{"key":"3562_CR145","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/978-1-4614-0554-2_24","volume-title":"Long acting injections and implants","author":"MN Martinez","year":"2012","unstructured":"Martinez MN, Khan MA. Regulatory issues and challenges associated with the development of performance specifications for modified release parenteral products. In: Wright JC, Burgess DJ, editors. Long acting injections and implants. Boston: Springer US; 2012. p. 505\u201335. https:\/\/doi.org\/10.1007\/978-1-4614-0554-2_24."},{"key":"3562_CR146","doi-asserted-by":"publisher","unstructured":"Liu T, Sun L, Ji Y, Zhu W. Extracellular vesicles in cancer therapy: Roles, potential application, and challenges. Biochim Biophys Acta (BBA) \u2013 Rev Cancer. 2024;1879(3):189101. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189101.","DOI":"10.1016\/j.bbcan.2024.189101"},{"issue":"12","key":"3562_CR147","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41571-025-01074-2","volume":"22","author":"DW Greening","year":"2025","unstructured":"Greening DW, Xu R, Rai A, Suwakulsiri W, Chen M, Simpson RJ. Clinical relevance of extracellular vesicles in cancer \u2014 therapeutic and diagnostic potential. Nat Rev Clin Oncol. 2025;22(12):924\u201352. https:\/\/doi.org\/10.1038\/s41571-025-01074-2.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3562_CR148","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12951-022-01526-2","volume":"20","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Zheng Y, Zhu Y, Li H, Zhu H, Liu T. Docetaxel-loaded M1 macrophage-derived exosomes for a safe and efficient chemoimmunotherapy of breast cancer. J Nanobiotechnol. 2022;20(1):359. https:\/\/doi.org\/10.1186\/s12951-022-01526-2.","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"3562_CR149","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1080\/10717544.2021.1951894","volume":"28","author":"Y Wang","year":"2021","unstructured":"Wang Y, Guo M, Lin D, Liang D, Zhao L, Zhao R. Docetaxel-loaded exosomes for targeting non-small cell lung cancer: preparation and evaluation in vitro and in vivo. Drug Deliv. 2021;28(1):1510\u201323. https:\/\/doi.org\/10.1080\/10717544.2021.1951894.","journal-title":"Drug Deliv"},{"issue":"1","key":"3562_CR150","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther. 2022;7(1):93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Sig Transduct Target Ther"},{"key":"3562_CR151","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2026.101634","volume":"64","author":"A Mansinho","year":"2026","unstructured":"Mansinho A, Albuquerque J, Barigazzi C, Calvo E. Antibody-drug conjugates in cancer treatment: from molecular design to clinical implementation. Lancet Reg Health Eur. 2026;64:101634. https:\/\/doi.org\/10.1016\/j.lanepe.2026.101634.","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"3562_CR152","doi-asserted-by":"publisher","first-page":"5089","DOI":"10.1021\/acs.molpharmaceut.8b00672","volume":"15","author":"DM Glatt","year":"2018","unstructured":"Glatt DM, Beckford Vera DR, Prabhu SS, Mumper RJ, Luft JC, Benhabbour SR, et al. Synthesis and characterization of cetuximab\u2013docetaxel and panitumumab\u2013docetaxel antibody\u2013drug conjugates for EGFR-overexpressing cancer therapy. Mol Pharm. 2018;15(11):5089\u2013102. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00672.","journal-title":"Mol Pharm"},{"issue":"1","key":"3562_CR153","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1080\/19420862.2016.1259047","volume":"9","author":"ML Geddie","year":"2017","unstructured":"Geddie ML, Kohli N, Kirpotin DB, Razlog M, Jiao Y, Kornaga T, et al. Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting. MAbs. 2017;9(1):58\u201367. https:\/\/doi.org\/10.1080\/19420862.2016.1259047.","journal-title":"MAbs"},{"key":"3562_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1355945","volume":"15","author":"M Demeule","year":"2024","unstructured":"Demeule M, Currie JC, Charfi C, Zgheib A, Cousineau I, Lullier V, et al. Sudocetaxel zendusortide (TH1902) triggers the cGAS\/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing. Front Immunol. 2024;15:1355945. https:\/\/doi.org\/10.3389\/fimmu.2024.1355945.","journal-title":"Front Immunol"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03562-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03562-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:30:26Z","timestamp":1790793026000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03562-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":154,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3562"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03562-9","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"assertion":[{"value":"6 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"319"}}